[1] 陈子祥,陈江明,耿小平,等. 病理组学技术在肝癌诊疗和预后评估中的应用和挑战. 中华外科杂志,2024,62(7):665-670. [2] Jia W, Rajani C, Xu H, et al. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.Protein Cell, 2021, 12(5): 374-393. [3] Chalasani N P, Ramasubramanian T S, Bhattacharya A, et al. A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma. Clin Gastroenterol H, 2021, 19(12): 2597-2605,e4. [4] 王正华,王明达,张晓谦. 超声造影诊断肝脏占位性病变良恶性效能分析. 实用肝脏病杂志,2024,27(4):607-610. [5] 于慧娟,邢丽丽,杨帆,等. 低剂量超声造影联合血清microRNA-1469水平在肝脏肿瘤良恶性诊断中的应用. 中华全科医学,2023,21(1):104-107. [6] Wang L, Shi H, Wei J, et al. SP70 is a novel biomarker of hepatocellular carcinoma. Front Oncol, 2023, 13: 1149397. [7] Mak L Y. Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma. Liver Cancer, 2024, 24(2): 145-154. [8] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版). 中华消化外科杂志,2022,21(2):143-168. [9] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263. [10] Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 2023, 77(5): 1773-1796. [11] Oldhafer K J, Habbel V, Horling K, et al. Benign liver tumors. Visc Med, 2020, 36(4): 292-303. [12] Gao Y X, Yang T W, Yin J M, et al. Progress and prospects of biomarkers in primary liver cancer. Int J Oncol, 2020, 57(1): 54-66. [13] Wilson S R, Burns P N, Kono Y. Contrast-enhanced ultrasound of focal liver masses: a success story. Ultrasound Med Biol, 2020, 46(5): 1059-1070. [14] Bartolotta T V, Taibbi A, Midiri M, et al. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand. Ultrasonography, 2019, 38(3): 200-214. [15] Schellhaas B, Strobel D. Tips and tricks in contrast-enhanced ultrasound (CEUS) for the characterization and detection of liver malignancies. UiM/EJU, 2019, 40(04): 404-424. [16] Tsili A C, Alexiou G, Naka C, et al. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis. Acta Radiol, 2021, 62(3): 302-312. [17] Mak L Y. Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma. Liver Cancer, 2024, 24(2): 145-154. [18] Toan B N, Tan C K, Hasan I, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol, 2023, 29(2): 277-292. [19] Tian S, Chen Y, Zhang Y, et al. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal, 2023, 37(1): e24823. [20] 张耀辉,郑章增,高星,等. 超声造影时间-强度曲线诊断肝硬化患者肝内小结节病灶价值研究. 实用肝脏病杂志,2022,25(6):861-864. |